b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">\n        <PMID Version="1">32257476</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>04</Month>\n            <Day>09</Day>\n        </DateRevised>\n        <Article PubModel="Electronic-eCollection">\n            <Journal>\n                <ISSN IssnType="Print">2090-6706</ISSN>\n                <JournalIssue CitedMedium="Print">\n                    <Volume>2020</Volume>\n                    <PubDate>\n                        <Year>2020</Year>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Case reports in oncological medicine</Title>\n                <ISOAbbreviation>Case Rep Oncol Med</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>4201727</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2020/4201727</ELocationID>\n            <Abstract>\n                <AbstractText>Tyrosine kinase inhibitor (TKI) combination is expected to increase in the era of precision medicine. TKI combination may be required to treat double primary cancers, each having a targetable gene, or to treat a single malignancy with multiple targetable genes. Here, we demonstrate the first report of dual EGFR and ABL TKI treatment in a patient with concomitant EGFR-mutated lung adenocarcinoma and BCR-ABL1-positive chronic myeloid leukemia (CML). A 60-year-old man with an 8-year history of CML was diagnosed as advanced EGFR-mutated lung adenocarcinoma. Complete molecular response of CML had been achieved by imatinib, and ABL-TKI had been switched to nilotinib four years previously due to muscle cramps. We discontinued nilotinib and started afatinib. Although partial response of lung adenocarcinoma was achieved, cytogenetic relapse of CML was observed following nilotinib discontinuation. We applied the previously described framework of cytochrome P450 3A4-mediated oral drug-drug interactions and selected gefitinib and nilotinib to treat both malignancies. We effectively and safely administered this combination for seven months. The present report is the first to demonstrate the safety and efficacy of dual EGFR and ABL TKI treatment in a patient with concomitant EGFR-mutated lung adenocarcinoma and CML.</AbstractText>\n                <CopyrightInformation>Copyright \xc2\xa9 2020 Kousuke Watanabe et al.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Watanabe</LastName>\n                    <ForeName>Kousuke</ForeName>\n                    <Initials>K</Initials>\n                    <Identifier Source="ORCID">https://orcid.org/0000-0003-4670-3679</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Respiratory Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Kage</LastName>\n                    <ForeName>Hidenori</ForeName>\n                    <Initials>H</Initials>\n                    <Identifier Source="ORCID">https://orcid.org/0000-0003-3658-4442</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Respiratory Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Nagoshi</LastName>\n                    <ForeName>Saki</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Respiratory Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Toyama</LastName>\n                    <ForeName>Kazuhiro</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ohno</LastName>\n                    <ForeName>Yoshiyuki</ForeName>\n                    <Initials>Y</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Shinozaki-Ushiku</LastName>\n                    <ForeName>Aya</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pathology, The University of Tokyo, Tokyo, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Nakazaki</LastName>\n                    <ForeName>Kumi</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Suzuki</LastName>\n                    <ForeName>Hiroshi</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Kurokawa</LastName>\n                    <ForeName>Mineo</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Nagase</LastName>\n                    <ForeName>Takahide</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Respiratory Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D002363">Case Reports</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2020</Year>\n                <Month>03</Month>\n                <Day>19</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Case Rep Oncol Med</MedlineTA>\n            <NlmUniqueID>101581035</NlmUniqueID>\n        </MedlineJournalInfo>\n        <CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>09</Month>\n                <Day>12</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2020</Year>\n                <Month>02</Month>\n                <Day>28</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2020</Year>\n                <Month>4</Month>\n                <Day>8</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2020</Year>\n                <Month>4</Month>\n                <Day>8</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>4</Month>\n                <Day>8</Day>\n                <Hour>6</Hour>\n                <Minute>1</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>epublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">32257476</ArticleId>\n            <ArticleId IdType="doi">10.1155/2020/4201727</ArticleId>\n            <ArticleId IdType="pmc">PMC7106872</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>Clin Pharmacokinet. 2009;48(10):653-66</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">19743887</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Respir Investig. 2017 Mar;55(2):181-183</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28274536</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2014 Feb 10;32(5):415-23</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24297946</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Br J Haematol. 2015 Jun;169(5):683-8</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25817799</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Br J Clin Pharmacol. 2018 Jun;84(6):1156-1169</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29381826</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2010 Mar 10;28(8):1387-94</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20142592</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Chemother Pharmacol. 2012 Apr;69(4):1051-61</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22200729</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Pharmacol. 2011 Jan;51(1):75-83</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20702754</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Med Oncol. 2018 May 30;35(7):99</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29846829</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Thorac Oncol. 2011 Jun;6(6):1128-31</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21623279</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Lancet Oncol. 2016 May;17(5):577-89</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27083334</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2002 Nov 1;20(21):4292-302</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">12409327</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2018 Jan 11;378(2):113-125</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29151359</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Pharmacol. 2015 Apr;55(4):401-8</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25418605</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Pharmacokinet. 2007;46(8):681-96</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">17655375</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Eur J Clin Pharmacol. 2008 Jan;64(1):31-41</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">18000659</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Med Invest. 2016;63(1-2):144-8</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27040071</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2001 Jul 1;19(13):3267-79</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">11432895</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>ESMO Open. 2016 Jul 21;1(4):e000063</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27843623</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Blood. 2011 Oct 20;118(16):4353-8</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21846902</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Pharmacokinet. 2005;44(10):1067-81</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">16176119</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'